A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Running, not enrolling · Phase 2/Phase 3

Conditions studied: X-Linked Retinitis Pigmentosa

In brief

This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.

Key facts

Study ID
NCT04850118
Run by
Beacon Therapeutics
People needed
85
Starts
2024-03-14
Expected to finish
2031-10-31
Last updated by the study team
2026-04-07

Who can join

Age: 12 and older, up to 50. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.